Chemomab Therapeutics Ltd. ADR (CMMB)
NASDAQ: CMMBHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
CMMB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $10.19M
- EPS (TTM)
- -$1.04
- Dividend yield
- None
- 52-week range
- 1.05 – 3.55
- Day range
- 1.36 – 1.44
- Volume / Avg
- 20.60K / 118.53K
- Beta
- —
- Shares outstanding
- 7.33M
- Next earnings
- Oct 8, 2026
52-week range
CMMB stock today
Chemomab Therapeutics (CMMB) closed at $1.39 on Oct 8, up 2.21% (+$0.03), versus the S&P 500's 0.47% decline. Trading was light, with 20.60K shares changing hands, about 17% of the average daily volume. Shares are 60.8% below their 52-week high of $3.55, set on Oct 9, 2025 and 32.3% above the 52-week low of $1.05, near the bottom of the past year's range.
CMMB is down 15.8% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 60.3%. Chemomab Therapeutics has posted a net loss over the last twelve months (EPS of -$1.04), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Oct 8.
Summary generated from market data by MetaCap's automated system. Methodology
About Chemomab Therapeutics
Company profileChemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Adi Mor George Ph.D.
- Headquarters
- Tel Aviv-Yafo
- IPO year
- 2019
- Website
- chemomab.com
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$5.00+259.71%
- Strong buy 1
- Buy 0
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 8, 2026
Chemomab Therapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SNTISenti Biosciences Holdings Inc. | 0.3217 | -2.52% | $10.02M | vs CMMB |
| TOVXTheriva Biologics Inc. | 0.2271 | -2.95% | $10.42M | vs CMMB |
| ADILAdial Pharmaceuticals Inc | 3.97 | -0.50% | $10.42M | vs CMMB |
| GTBPGT Biopharma Inc. | 5.96 | -3.87% | $10.75M | vs CMMB |
| VTGNVistagen Therapeutics Inc. | 0.2462 | -0.36% | $10.93M | vs CMMB |
| BLRXBioLineRx Ltd. ADR | 2.21 | +0.23% | $11.00M | vs CMMB |
| BIVIBioVie Inc. Class A | 1.28 | -8.57% | $11.11M | vs CMMB |
| KPRXKiora Pharmaceuticals Inc. | 2.53 | 0.00% | $11.19M | vs CMMB |
Indexes, lists and sector
Appears in lists
Chemomab Therapeutics stock FAQ
What is Chemomab Therapeutics's stock price today?
CMMB last traded at $1.39 as of Oct 8, 4:00 PM EDT, up 2.21% on the day. Prices are delayed at least 15 minutes.
Does Chemomab Therapeutics pay a dividend?
No. Chemomab Therapeutics does not currently pay a regular cash dividend.
When is Chemomab Therapeutics's next earnings date?
Chemomab Therapeutics is expected to report earnings on Thursday, October 8, 2026.
Who is Chemomab Therapeutics's CEO?
Dr. Adi Mor George Ph.D. is the chief executive officer of Chemomab Therapeutics Ltd. ADR.
Has CMMB ever split its stock?
Yes. The most recent CMMB stock split was a 1-for-4 split on Aug 26, 2025, one of 2 splits on record.
What is the CMMB 52-week high?
The 52-week high for CMMB is $3.55 and the 52-week low is $1.05. The stock is currently 60.8% below its high.